Skip to content
10-Q

Quarterly Report

REGENERX BIOPHARMACEUTICALS, INC.

0001104659-21-139207

← back to feed
Filed
Nov 15, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Nov 10, 2021 143.55M sh
Cash And Equivalents Q3 2021 · Sep 30, 2021 $1.52M
Cash And Equivalents Q3 2021 · Dec 31, 2020 $427.9K
Current Liabilities Q3 2021 · Sep 30, 2021 $417.5K
Current Liabilities Q3 2021 · Dec 31, 2020 $399.58K
Total Liabilities Q3 2021 · Sep 30, 2021 $3.46M
Total Liabilities Q3 2021 · Dec 31, 2020 $3.38M
Current Assets Q3 2021 · Sep 30, 2021 $1.55M
Current Assets Q3 2021 · Dec 31, 2020 $477.81K
Total Assets Q3 2021 · Sep 30, 2021 $1.59M
Total Assets Q3 2021 · Dec 31, 2020 $551.79K
Shares Diluted Q3 2021 · Sep 30, 2020 133.44M sh
Shares Diluted Q3 2021 · Sep 30, 2020 133.33M sh
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$798.42K
Stockholders Equity Q3 2021 · Sep 30, 2020 −$2.98M
Stockholders Equity Q3 2021 · Jun 30, 2020 −$2.72M
Stockholders Equity Q3 2021 · Mar 31, 2020 −$2.44M
Stockholders Equity Q3 2021 · Dec 31, 2019 −$2.34M
Eps Diluted Q3 2021 · Sep 30, 2020 $0.00
Eps Diluted Q3 2021 · Sep 30, 2020 −$0.01
Eps Basic Q3 2021 · Sep 30, 2020 $0.00
Eps Basic Q3 2021 · Sep 30, 2020 −$0.01
Sga Expense restated Q3 2021 · Sep 30, 2020 $299.16K
Sga Expense restated Q3 2021 · Sep 30, 2020 $1.06M
Rd Expense restated Q3 2021 · Sep 30, 2020 $482
Rd Expense restated Q3 2021 · Sep 30, 2020 $4.43K
Net Income Q3 2021 · Sep 30, 2020 −$332.6K
Net Income Q3 2021 · Sep 30, 2020 −$1.16M
Net Income Q3 2021 · Jun 30, 2020 −$436.16K
Net Income Q3 2021 · Mar 31, 2020 −$386.73K
Operating Income Q3 2021 · Sep 30, 2020 −$280.45K
Operating Income Q3 2021 · Sep 30, 2020 −$1M
Revenue Q3 2021 · Sep 30, 2020 $19.19K
Revenue Q3 2021 · Sep 30, 2020 $57.57K